Search

Your search keyword '"Viguier, M."' showing total 911 results
Start Over Author "Viguier, M."
911 results on '"Viguier, M."'

1. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm

Author

Poizeau, F., Leducq, S., Fardet, L., Beylot-Barry, M., Chaby, Guillaume, Chastagner, M., Corgibet, F., Gouillon, L., Jouan, N., Jullien, D., Acher, A., Amatore, F., Amici, J.-M., Aubert, H., Aubin, F., Beneton, N., Bouilly, D, Bursztejn, A.-C., Buzenet, C., Chamaillard-Pujol, M., Charles, J., Cottencin-Charriere, A.-C., Duval Modeste, B., Fauconneau, A., Fougerousse, A.-C., Girard, C., Goujon, C., Khemis, A., Le Ru, Y., Lepelley-Dupont, C., Mahé, E., Marcellin, X., Nicolas, C., Pallure, V., Parier, J., Quiles, N., Stoebner, P.-E., Tauber, M., Vermersch, A., Viguier, M., Villani, A.P., Chosidow, O., and Guillot, B.

Published
2024
Full Text
View/download PDF

8. Actualisation des recommandations françaises de traitement du pemphigus

Author

Jelti, L., Prost-Squarcioni, C., Ingen-Housz-Oro, S., Caux, F., Bernard, P., Bedane, C., Alexandre, M., Dereure, O., Quereux, G., Le Bidre, E., Plée, J., Picard-Dahan, C., Le Roux-Villet, C., Duvert-Lehembre, S., Richard, M.-A., Delaporte, E., Debarbieux, S., Jullien, D., D’Incan, M., Konstantinou, M.-P., Bouaziz, J.-D., Tancrède-Bohin, E., Doutre, M.-S., Bourgault Villada, I., Cordel, N., Sassolas, B., Viguier, M.-A., Mellottée, B., Jouen, F., Hebert, V., and Joly, P.

Published
2019
Full Text
View/download PDF

15. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française Psobioteq

Author

Curmin, R., primary, Guillo, S., additional, de Rycke, Y., additional, Beylot-Barry, M., additional, Beneton, N., additional, Chosidow, O., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Richard, M.A., additional, Viguier, M., additional, Sbidian, E., additional, Paul, C., additional, Bachelez, H., additional, Mahé, E., additional, and Tubach, F., additional

Published
2022
Full Text
View/download PDF

16. Tanorexie et psoriasis sévère

Author

Mahé, E., primary, Curmin, R., additional, Paul, C., additional, Bachelez, H., additional, Sbidian, E., additional, Beylot-Barry, M., additional, Beneton, N., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Richard, M.A., additional, Viguier, M., additional, Chosidow, O., additional, and Tubach, F., additional

Published
2022
Full Text
View/download PDF

17. Impact de la voie d’administration du méthotrexate sur son maintien en monothérapie dans le psoriasis cutané : données issues de la cohorte PSOBIOTEQ

Author

Paris, C., primary, Gouillon, L., additional, Curmin, R., additional, De, R.Y., additional, Bachelez, H., additional, Beneton, N., additional, Beylot-Barry, M., additional, Dupuy, A., additional, Joly, P., additional, Mahé, E., additional, Paul, C., additional, Richard, M.A., additional, Sbidian, E., additional, Viguier, M., additional, Chosidow, O., additional, Tubach, F., additional, and Jullien, D., additional

Published
2022
Full Text
View/download PDF

18. Survie globale et prise en charge du syndrome de Sézary : étude rétrospective multicentrique de 402 cas

Author

Bozonnat, A., primary, Beylot-Barry, M., additional, Dereure, O., additional, D’Incan, M., additional, Quéreux, G., additional, Guenova, E., additional, Grange, F., additional, Viguier, M., additional, Ram-Wolff, C., additional, Boulinguez, S., additional, Troin, L., additional, Montaudié, H., additional, Feldmeyer, L., additional, Beltraminelli, H., additional, Bonnet, N., additional, Maubec, E., additional, Franck, N., additional, Machet, L., additional, Chasset, F., additional, Saiag, P., additional, Hainault, E., additional, Brunet Possenti, F., additional, Michel, C., additional, Bens, G., additional, Adamski, H., additional, Aubin, F., additional, Faiz, S., additional, Mortier, L., additional, Joly, P., additional, Tedbirt, B., additional, Templier, I., additional, Bouaziz, J.D., additional, Battistella, M., additional, Oro, S., additional, Bagot, M., additional, Serret-Larmande, A., additional, Montlahuc, C., additional, and de Masson, A., additional

Published
2022
Full Text
View/download PDF

19. Efficacité et tolérance du dupilumab dans la pemphigoïde bulleuse : étude rétrospective multicentrique

Author

Moghadam, P., primary, Tancrede, E., additional, Bouaziz, J.D., additional, Bedane, C., additional, Begon, E., additional, Bourgault Villada, I., additional, Calugareanu, A., additional, Dereure, O., additional, Jendoubi, F., additional, Pham-Ledard, A., additional, Oro, S., additional, Picard-Dahan, C., additional, Viguier, M., additional, Alexandre, M., additional, and Lepelletier, C., additional

Published
2022
Full Text
View/download PDF

20. Étude de la tolérance de la vaccination anti-SARS-CoV-2 chez les patients atteints de maladies bulleuses auto-immunes

Author

Ou, S., primary, Tancrede, E., additional, Alexandre, M., additional, Oro, S., additional, Jelti, L., additional, Castel, M., additional, Debarbieux, S., additional, Calugareanu, A., additional, Duvert Lehembre, S., additional, Konstantinou, M.P., additional, Veron, M., additional, Abasq, C., additional, Berthin, C., additional, Couzan, C., additional, Caux, F., additional, Joly, P., additional, and Viguier, M., additional

Published
2022
Full Text
View/download PDF

23. Étude descriptive multicentrique des schémas d’adaptation en cas de réponse inadéquate au dupilumab dans la dermatite atopique en France

Author

Strizzolo, R., primary, Soria, A., additional, Jachiet, M., additional, Tauber, M., additional, Seneschal, J., additional, Clément, A., additional, Staumont-Sallé, D., additional, Barbarot, S., additional, Raison Peyron, N., additional, Viguier, M., additional, Mallet, S., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

24. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

25. Étude de l’efficacité clinique et humorale de la vaccination anti-SARS-CoV-2 chez les patients atteints de maladies bulleuses auto-immunes

Author

Ou, S., primary, Tancrede, E., additional, Alexandre, M., additional, Oro, S., additional, Jelti, L., additional, Bouteiller, J., additional, Debarbieux, S., additional, Calugareanu, A., additional, Duvert Lehembre, S., additional, Berthin, C., additional, Caux, F., additional, Joly, P., additional, and Viguier, M., additional

Published
2022
Full Text
View/download PDF

27. Utilisation des traitements systémiques pour la prise en charge du psoriasis modéré à sévère : consensus d’experts par méthode DELPHI

Author

Poizeau, F., primary, Leducq, S., additional, Guillot, B., additional, Beylot-Barry, M., additional, Chaby, G., additional, Chastagner, M., additional, Corgibet, F., additional, Gouillon, L., additional, Jullien, D., additional, Acher, A., additional, Amatore, F., additional, Amici, J.M., additional, Aubert, H., additional, Aubin, F., additional, Beneton, N., additional, Bouilly, D., additional, Bursztejn, A.C., additional, Buzenet, C., additional, Chamaillard-Pujol, M., additional, Charles, J., additional, Cottencin-Charriere, A.C., additional, Duval, M.B., additional, Fauconneau, A., additional, Fougerousse, A.C., additional, Girard, C., additional, Goujon, C., additional, Khemis, A., additional, Le Ru, Y., additional, Lepelley-Dupont, C., additional, Mahé, E., additional, Marcellin, X., additional, Nicolas, C., additional, Pallure, V., additional, Parier, J., additional, Paul, C., additional, Quiles, N., additional, Richard, M.A., additional, Stoebner, P.E., additional, Tauber, M., additional, Vermersch, A., additional, Viguier, M., additional, Villani, A., additional, Chosidow, O., additional, and Fardet, L., additional

Published
2022
Full Text
View/download PDF

32. Incidence et mortalité de la pemphigoïde des muqueuses en France

Author

Lefebvre, A., Gillibert, A., Tancrede, E., Loridon, L., Lepelletier, C., Lombart, F., Pham-Ledard, A., Abasq-Thomas, C., Oro, S., Duvert Lehembre, S., Modiano, P., Becquart, C., Bedane, C., Quéreux, G., Picard-Dahan, C., Dupin, N., Viguier, M., Muller, C., Chastagner, M., Jullien, D., Jeudy, G., Richard, M.A., Morice, C., Litrowski, N., Debarbieux, S., Grosjean, J., Hebert, V., Joly, P., and Tedbirt, B.

Abstract

L’incidence de la pemphigoïde des muqueuses (PM) a été estimée à 1,2 cas/M d’habitants/an en 1995 dans 3 régions françaises. Par ailleurs, aucune étude n’a estimé le taux de mortalité standardisé (SMR). Les objectifs de cette étude étaient de calculer l’incidence de la PM en France entre 2012 et 2021, les SMR et d’identifier les facteurs pronostiques de mortalité.

Published
2024
Full Text
View/download PDF

33. Le pemphigus herpétiforme peut s’accompagner d’une atteinte muqueuse et d’auto-anticorps anti-desmogléine 3, remettant en question sa classification en pemphigus superficiel

Author

Perceau, M., Alexandre, M., Debarbieux, S., Lombart, F., and Viguier, M.

Abstract

Le pemphigus herpétiforme (PH) est caractérisé par des lésions urticariennes annulaires, avec des bulles (ou vésicules) à disposition herpétiforme. Le diagnostic repose sur cette présentation clinique et une immunofluorescence cutanée directe (IFD) de type pemphigus. Cette entité a été décrite en 1975 comme une sous-catégorie de pemphigus superficiel (PS), car le plus souvent associée à une atteinte cutanée isolée et à la positivité des anticorps (ac) anti-desmogléine (DSG)-1.

Published
2024
Full Text
View/download PDF

37. Éruptions eczématiformes chroniques du sujet âgé : quelle imputabilité médicamenteuse ?

Author

Bouteiller, J., primary, Grosjean, J., additional, Delaunay, J., additional, Jachiet, M., additional, Bara, C., additional, Nosbaum, A., additional, Bouschon, P., additional, Milpied, B., additional, Oro, S., additional, Assier, H., additional, Guelimi, R., additional, Valois, A., additional, Viguier, M., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Boulard, C., additional, Brenaut, E., additional, Morice, C., additional, Raison Peyron, N., additional, Joly, P., additional, and Tetart, F., additional

Published
2022
Full Text
View/download PDF

39. Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohortPSOBIOTEQ.

Author

Curmin, R., Guillo, S., De Rycke, Y., Bachelez, H., Beylot‐Barry, M., Beneton, N., Chosidow, O., Dupuy, A., Joly, P., Jullien, D., Richard, M.A., Viguier, M., Sbidian, E., Paul, C., Mahé, E., and Tubach, F.

Subjects
BIOLOGICALS, PSORIASIS, TUMOR necrosis factors, COMPETING risks, SURVIVAL analysis (Biometry)
Abstract

Background: Biologics are the cornerstone of treatment of patients with moderate‐to‐severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. Objectives: The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. Methods: We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate‐to‐severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra‐class – i.e. within the same therapeutic class ‐ vs. inter‐class) in patients switching from a TNF‐alpha inhibitor using multivariate logistic regression. Results: A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF‐alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL‐17 inhibitor. Patients switching from a first‐line TNF‐alpha inhibitor before 2016 were more likely to switch to another TNF‐alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF‐alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. Conclusion: This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL‐17 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort

Author

Beylot‐Barry, M., primary, Seneschal, J., additional, Tran, D., additional, Bachelez, H., additional, Beneton, N., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Mahé, E., additional, Paul, C., additional, Richard, M.‐A., additional, Sbidian, E., additional, Viguier, M., additional, Chosidow, O., additional, and Tubach, F., additional

Published
2021
Full Text
View/download PDF

45. Facteurs de risque de mortalité des dermatomyosites associées à un cancer : une étude de cohorte rétrospective multicentrique de 73 patients

Author

Teboul, A., Allenbach, Y., Tubach, F., Cassius, C., Demortier, J., Dossier, A., Faucon, C., Kasser, C., Mékinian, A., Monseau, G., Fouchard, M., Chambrelan, E., Viguier, M., Kluger, N., Mahévas, T., Bergeret, B., Bachmeyer, C., Lenormand, C., Hotz, C., Diaz, E., Benveniste, O., Bessis, D., Cordel, N., Bouaziz, J.D., and Chasset, F.

Published
2023
Full Text
View/download PDF

46. Cémiplimab versus traitements systémiques historiques du carcinome épidermoïde cutané localement avancé ou métastatique : résultats de l’étude TOSCA

Author

Gerard, E., Lebbé, C., Lanoy, E., Quéreux, G., Bernard, P., Viguier, M., Meyer, N., Mortier, L., Dinulescu, M., Legoupil, D., Neidhardt, E.M., Saiag, P., Trabelsi, S., Célérier, P., Nardin, C., Maubec, E., Duval-Modeste, A.B., Hainault, E., Darras, S., Maillard, H., Guégan, S., Arnault, J.P., Stoebner, P.E., Le Corre, Y., Grange, F., Peuvrel, L., Bonniaud, B., Herrscher, H., Granel-Brocard, F., Vataire, A.L., Perrier, S., Tabellion, A., Garnier, S., and Robert, C.

Published
2023
Full Text
View/download PDF

47. Avélumab en traitement de 1re ligne des patients atteints d’un carcinome à cellules de Merkel métastatique : analyse des données en vie réelle en France à partir de bases de données de cancers rares et du Système National de Données de Santé (SNDS)

Author

Blom, A., Mortier, L., van Hille, B., Pagès, C., Samimi, M., Luciani, L., Cahuzac, C., Robert, C., Quéreux, G., Maubec, E., Maillard, C., Miotti, H., Aubin, F., Arnault, J.P., Dompmartin, A., Mansard, S., Dereure, O., Montaudié, H., Amini-Adle, M., Viguier, M., Kramkimel, N., Granel-Brocard, F., Gaudy-Marqueste, C., Zehou, O., Jeudy, G., Bernard, P., De Quatrebarbes, J., Leccia, M.T., Le Corre, Y., Beneton, N., Wierzbicka-Hainaut, E., Brunet Possenti, F., Lenormand, C., Solbes, M.N., Duval-Modeste, A.B., Kachaner, I., Lebbé, C., Dutriaux, C., and Saiag, P.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results